A case report and review looked at a 68-year-old man with stage IV lung adenocarcinoma. He had a specific mutation known as EGFR p.E709_T710delinsD and had tumors in his brain. He was treated with 30 mg of afatinib once daily.
Despite the treatment, the patient's disease progressed rapidly within just five weeks. This suggests that for some patients with high disease burden and aggressive tumor biology, this specific mutation may not provide an initial benefit. The study notes that this does not mean the mutation is always resistant to afatinib, but it can behave this way in certain cases.
Because the evidence comes from a single case report and a review, the findings are limited. There was no tissue or molecular evidence to confirm the exact reason for the resistance. Doctors recommend that patients who show rapid progression undergo early imaging, repeat biopsies, or blood tests to check for changing mutations.
Common questions
What did the study find about the afatinib treatment?
The study followed one patient with a specific lung cancer mutation who took 30 mg of afatinib daily. In this specific case, the disease progressed rapidly within five weeks. This suggests that for some patients with aggressive tumor biology, this mutation might not provide an initial benefit.
Is this mutation always resistant to afatinib?
No, the report does not say that the EGFR p.E709_T710delinsD variant is always resistant to afatinib. However, it suggests that in some cases with high disease burden, the mutation may show a phenotype of rapid progression. You should talk to your doctor about your specific results.
What should happen if a patient's cancer progresses quickly?
For cases where cancer progresses rapidly, the report suggests early radiographic reassessment. Doctors may also recommend a repeat biopsy or ctDNA testing to check for changes in the tumor's molecular makeup. Consult your medical team to determine the best follow-up steps.
